Neurocrine Bio. (NBIX) Jumps on New "Overweight" Rating at Morgan Stanley
Tweet Send to a FriendGet Alerts NBIX Hot Sheet
Price: $11.75 -2%
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade NBIX Now!
Neurocrine Bio. (NASDAQ: NBIX) is 4 percent higher Thursday after Morgan Stanley initiated coverage on the stock with an Overweight rating and $12 price target.
The firm is positive on Elagolix and sees 2020 sales of approx. $720 million.
For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.
Shares of Neurocrine Bio. closed at $8.30 yesterday, with a 52 week range of $5.42-$9.98.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm is positive on Elagolix and sees 2020 sales of approx. $720 million.
For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.
Shares of Neurocrine Bio. closed at $8.30 yesterday, with a 52 week range of $5.42-$9.98.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Barclays Starts T-Mobile US, (TMUS) at Equalweight
- Topeka Capital Starts Precision Castparts (PCP) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Morgan Stanley
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
